Arbeitskreis Klinische Studien Report issue

Academic/Hospital Phase 1 Phase 3

Organization Overview

First Clinical Trial
2009
NCT00868634
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (3)

bevacizumab (avastin) (1 trial)

capecitabine (xeloda) (2 trials)

vinorelbine (navelbine) (2 trials)

Drugs in Phase 1 Trials (1)

lapatinib (tykerb) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 4